A curated map of eleven foundational and validating studies, five completed interventional trials, and the patent families claiming rights on the bacteria they identify.
11 papers5 trials5 patent assignees4 themesSmart Citations via Scite
Year
Study type
11 / 11 visible
Completed trials referenced
NCT03341143
FMT + pembrolizumab in PD-1–refractory melanoma. Phase II, UPMC/Merck. n=18. Completed Sept 2024.
→ Davar 2021, Science
NCT04116775
FMT + pembro + enzalutamide in mCRPC. Phase II, Portland VA. n=32 anticipated. Completed Oct 2023.
NCT04729322
FMT + pembro/nivo re-challenge in MSI-H mCRC. Phase II, MD Anderson/NCI. Completed Dec 2024.
NCT04951583
FMT + ICI in NSCLC / melanoma / uveal. Phase II, CHUM Canada (Routy group). Completed Sept 2025.
NCT03829111
CBM588 + nivo/ipi in mRCC. Phase I, City of Hope. n=30. Completed June 2024.
→ Dizman 2022, Nature Medicine. PFS 12.7 vs 2.5 mo (HR 0.15). Microbiome 1° endpoint not met.
Patent assignees & key filings
Gustave Roussy
Zitvogel lab, 7+ families.
WO 2018/115519 · US 2019/0282632 · US 2022/0370514 · US 2024/0288449 · US 2024/0398876 · WO 2020/064997 (via Everimmune / INSERM / Paris-Saclay)
Evelo
Bacterial EVs & membrane preps (dissolved 2024).
US 12,109,243 · US 2022/0118030 · US 2022/0296654 · US 2021/0052669
4D Pharma
Roseburia franchise via GT Biologics / Armistice Capital.
US 11,266,698 (R. hominis) · US 11,414,463 (R. flagellin)
U. Chicago
Gajewski — foundational Bifidobacterium + ICI IP.
US 9,855,302 · inventors Gajewski, Sivan, Corrales
MD Anderson
Wargo / Gopalakrishnan, cross-assigned with Zitvogel.